SCHEMBL4663829

SCHEMBL4663829

CN(C)CCn1ncc2cc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5c(F)cccc5F)cc4)ncn3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.39
JAK3 P52333 3/20 0.39
JAK1 P23458 2/20 0.39
JAK2 O60674 1/20 0.39
MAPK1 P28482 2/20 0.38
USP2 O75604 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CLK4 Q9HAZ1 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
GLA P06280 1/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663840 0.93 EGFR (0.40) EGFRJAK3JAK1JAK2MAPK1
SCHEMBL4667434 0.89 MAPK1 (0.37) EGFRJAK3JAK1JAK2MAPK1
SCHEMBL4665797 0.88 EGFR (0.38) EGFRJAK3JAK1JAK2MAPK1
Formic Acid SCHEMBL4663826 0.84 JAK1 (0.42) EGFRJAK3JAK1JAK2MAPK1
SCHEMBL4663971 0.83 MAPK1 (0.37) EGFRJAK3JAK1JAK2MAPK1
SCHEMBL4665826 0.82 HTR6 (0.41) EGFRMAPK1USP2CYP1A2CYP3A4
Formic Acid SCHEMBL4663834 0.81 JAK1 (0.40) EGFRJAK3JAK1JAK2MAPK1
SCHEMBL4666122 0.81 BPTF (0.39) EGFRMAPK1USP2CYP1A2CYP3A4
SCHEMBL4665786 0.80 BPTF (0.38) EGFRMAPK1USP2CYP1A2CYP3A4
SCHEMBL4666171 0.79 ABL1 (0.36) EGFRMAPK1USP2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 EGFR 279/4885JAK3 79/4885JAK1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.